Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

Marlise R. Luskin, Mark Alan Murakami, Julia H. Keating, Yael Flamand, Eric S Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella Louise Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S Wang, Wendy Stock, Daniel J DeAngelo

Blood blood.2024025800.

https://doi.org/10.1182/blood.2024025800

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Manik Razdan Kuchroo, Robert A. Redd, Jacqueline S. Garcia, Michael Keng, Gabriela S. Hobbs, Jacalyn Rosenblatt, Marlise R. Luskin, Rupa Narayan, Philip C. Amrein, Malgorzata McMasters, Martha Wadleigh, Hanno Hock, Richard Stone, Donna S. Neuberg, David Avigan, Karen K. Ballen, Amir T. Fathi, Daniel J. DeAngelo, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2023-188182

Published: 2023

Journal Articles

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Blood (2023) 142 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2023-180010

Published: 2023

Journal Articles

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Hari S. Raman, Shai Shimony, Yannis K. Valtis, Yael Flamand, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin

Blood (2023) 142 (Supplement 1): 1456.

https://doi.org/10.1182/blood-2023-178353

Published: 2023

Journal Articles

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Mahasweta Gooptu, Haesook T. Kim, Kaina Chen, Ann Mullally, Joseph Antin, Corey Cutler, Amar H Kelkar, John Koreth, Roman M. Shapiro, Robert J. Soiffer, Daniel J. DeAngelo, Jacqueline S. Garcia, Marlise R. Luskin, Richard M Stone, Martha Wadleigh, Eric S. Winer, R. Coleman Lindsley, Vincent Ho

Blood (2023) 142 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2023-178684

Published: 2023

Journal Articles

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Eric S. Winer, Jacqueline S. Garcia, Richard M Stone, Martha Wadleigh, Marlise R. Luskin, Maximilian Stahl, Evan C. Chen, Rebecca Leonard, Alexis Noyes, Ilene Galinsky, Rashmi Deshpande, Pascal Borderies, Vincent O'Neill, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2023-186598

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2023-181014

Published: 2023

Journal Articles

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

Blood (2023) 142 (Supplement 1): 999.

https://doi.org/10.1182/blood-2023-187519

Published: 2023

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Marlise R. Luskin, Mark Alan Murakami, Julia Keating, Eric S. Winer, Jacqueline S. Garcia, Maximilian Stahl, Martha Wadleigh, Yael Flamand, Donna S. Neuberg, Ilene Galinsky, Rebecca Leonard, Ella Hagopian, Chase M Weizer, Carlin McLanahan, Richard M Stone, Eunice S. Wang, Wendy Stock, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 965.

https://doi.org/10.1182/blood-2023-174246

Published: 2023

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Blood (2023) 141 (15): 1884–1888.

https://doi.org/10.1182/blood.2022017686

Published: 2023

Includes: Supplemental data

Journal Articles

Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials

Shai Shimony, Yael Flamand, Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Richard M. Stone, Martha Wadleigh, Donna S. Neuberg, Daniel J DeAngelo, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 3164–3165.

https://doi.org/10.1182/blood-2022-158348

Published: 2022

Journal Articles

Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Richard M. Stone, Daniel J DeAngelo, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 8901–8903.

https://doi.org/10.1182/blood-2022-159286

Published: 2022

Journal Articles

Intensity of Induction Regimen and Outcomes Among Adults with Ph+ ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hari S. Raman, Se Eun Kim, Daniel J DeAngelo, Kristen E. Stevenson, Donna S. Neuberg, Eric S. Winer, Martha Wadleigh, Jacqueline S. Garcia, Annette S. Kim, Richard M. Stone, Vincent T Ho, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 8882–8883.

https://doi.org/10.1182/blood-2022-163854

Published: 2022

Journal Articles

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Blood (2022) 140 (Supplement 1): 917–919.

https://doi.org/10.1182/blood-2022-157611

Published: 2022

Journal Articles

Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)

Maximilian F. Stahl, Gerard Giblin, Yiwen Liu, Daniel J DeAngelo, Richard M. Stone, Eric S. Winer, Martha Wadleigh, Coleman Lindsley, Shai Shimony, Kevin Copson, Anne Charles, Anju Nohria, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 6067–6068.

https://doi.org/10.1182/blood-2022-159193

Published: 2022

Journal Articles

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3- wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Shai Shimony, Geoffrey G Fell, Evan C. Chen, Harrison Tsai, Martha Wadleigh, Eric S. Winer, Jacqueline S. Garcia, Marlise R. Luskin, Maximilian F. Stahl, Donna S. Neuberg, Daniel J DeAngelo, R. Coleman Lindsley, Richard M. Stone

Blood (2022) 140 (Supplement 1): 8938–8939.

https://doi.org/10.1182/blood-2022-162716

Published: 2022

Journal Articles

Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax

Evan C. Chen, Yiwen Liu, Eric S. Winer, Marlise R. Luskin, Martha Wadleigh, Andrew A. Lane, Rahul S. Vedula, Coleman Lindsley, Kevin Copson, Anne Charles, Donna S. Neuberg, Nicolas C. Issa, Daniel J. DeAngelo, Richard M. Stone, Jacqueline S. Garcia

Blood (2021) 138 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2021-148717

Published: 2021

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults

Marlise R. Luskin, Kristen E. Stevenson, Lourdes M. Mendez, Eunice S. Wang, Martha Wadleigh, Jacqueline S. Garcia, Richard M. Stone, Hyun Hwan An, Ella Hagopian, Ilene Galinsky, Lindsey Rae, Rebecca Leonard, Daniel J. DeAngelo, Mark A. Murakami

Blood (2021) 138 (Supplement 1): 2305.

https://doi.org/10.1182/blood-2021-149225

Published: 2021

NARROW

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials

Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival

Intensity of Induction Regimen and Outcomes Among Adults with Ph+ ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3- wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only